[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(857) 330-4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 65, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 51, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 46, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Thompson M.A., M.S., Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 64, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kurt C. Gunter FASCP, M.D., Ph.D.", "age": 68, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.42, "open": 4.38, "dayLow": 4.38, "dayHigh": 4.55, "regularMarketPreviousClose": 4.42, "regularMarketOpen": 4.38, "regularMarketDayLow": 4.38, "regularMarketDayHigh": 4.55, "beta": 1.367, "forwardPE": -2.75625, "volume": 629384, "regularMarketVolume": 629384, "averageVolume": 690900, "averageVolume10days": 595180, "averageDailyVolume10Day": 595180, "bid": 4.4, "ask": 4.43, "bidSize": 200, "askSize": 200, "marketCap": 272414496, "fiftyTwoWeekLow": 2.689, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 5.7516, "twoHundredDayAverage": 4.71545, "currency": "USD", "enterpriseValue": 130417416, "floatShares": 34171640, "sharesOutstanding": 61772000, "sharesShort": 3153357, "sharesShortPriorMonth": 2382573, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.051, "heldPercentInsiders": 0.00657, "heldPercentInstitutions": 0.92977, "shortRatio": 3.24, "shortPercentOfFloat": 0.0514, "impliedSharesOutstanding": 61772000, "bookValue": 2.274, "priceToBook": 1.939314, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -71169000, "trailingEps": -1.37, "forwardEps": -1.6, "pegRatio": -0.22, "enterpriseToEbitda": -1.743, "52WeekChange": -0.24226803, "SandP52WeekChange": 0.23099434, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.41, "targetHighPrice": 40.0, "targetLowPrice": 14.0, "targetMeanPrice": 20.33, "targetMedianPrice": 15.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 188588992, "totalCashPerShare": 3.053, "ebitda": -74812000, "totalDebt": 46592000, "quickRatio": 12.868, "currentRatio": 13.363, "debtToEquity": 33.167, "returnOnAssets": -0.27807, "returnOnEquity": -0.54984003, "freeCashflow": -46046248, "operatingCashflow": -70675000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]